Objective:

To examine treatment considerations and outcomes of spinal ependymomas, particularly in pediatric cases, focusing on molecular classification and clinical management.

Approach:

• Management Overview: Management involves tissue diagnosis, histopathological and molecular characterization, and surgical resection, with adjuvant radiotherapy for higher-grade tumors.
• Molecular Classification: The WHO classification recognizes four entities: SP-EPN, SP-EPN-MYCN, SP-SE, and SP-MPE, with emphasis on integrated diagnosis combining histology and molecular features.
• Clinical Presentation: Symptoms include progressive sensory abnormalities, gait imbalance, motor weakness, and axial back pain, with delayed diagnosis common in pediatric patients.
• Neurological Imaging: Gadolinium-enhanced MRI is essential for diagnosis and staging, with comprehensive neuraxis imaging recommended to exclude synchronous disease.

Key Findings:

• Spinal ependymomas are rare in children, comprising 1% of childhood CNS neoplasms.
• Surgical resection is associated with improved progression-free and overall survival rates.
• MYCN amplification in SP-EPN-MYCN indicates a more aggressive disease course.
• Pediatric SP-MPE cases show variability in progression-free survival based on methylation subtype.

Interpretation:

Surgical resection and histologic grade are the primary determinants of outcomes in pediatric spinal ependymomas, while molecular profiling aids in classification.

Limitations:

• The study does not provide a systematic review of all literature.
• Long-term outcomes and recurrence risks may vary and require further investigation.

Conclusion:

Lifelong surveillance is necessary due to risks of late recurrence and distant disease in spinal ependymomas.

Sources:

• WHO CNS Tumor Classification